Symbols / BMRA Stock $2.35 -1.26% Biomerica, Inc.

Healthcare • Medical Devices • United States • NCM
BMRA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Zackary S. Irani
Exch · Country NCM · United States
Market Cap 7.26M
Enterprise Value 6.12M
Income -4.17M
Sales 4.33M
FCF (ttm) -2.03M
Book/sh 1.09
Cash/sh 0.43
Employees 53
Insider 10d —
IPO Sep 07, 1984
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 6.03
PEG —
P/S 1.68
P/B 2.15
P/C —
EV/EBITDA -1.16
EV/Sales 1.41
Quick Ratio 1.46
Current Ratio 2.64
Debt/Eq 5.82
LT Debt/Eq —
EPS (ttm) -1.61
EPS next Y 0.39
EPS Growth —
Revenue Growth -11.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-04-14
Earnings (prior) 2023-04-14
ROA -54.58%
ROE -94.32%
ROIC —
Gross Margin 4.37%
Oper. Margin -131.51%
Profit Margin -96.46%
Shs Outstand 3.09M
Shs Float 2.77M
Insider Own 15.24%
Instit Own 3.62%
Short Float 2.31%
Short Ratio 4.24
Short Interest 63.38K
52W High 4.60
vs 52W High -48.91%
52W Low 1.87
vs 52W Low 25.67%
Beta 0.28
Impl. Vol. —
Rel Volume 0.41
Avg Volume 22.60K
Volume 9.24K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $2.38
Price $2.35
Change -1.26%
About

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$2.35
Latest analyst target
3. DCF / Fair value
$-11.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.35
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2020-10-19 main Aegis Capital — → Buy $11
2020-09-04 main Aegis Capital — → Buy $13
2020-08-21 init Aegis Capital — → Buy $10
2018-12-17 main B. Riley Securities Buy → Buy $6
News
RSS: Latest BMRA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-12 IRANI ZACKARY S Chief Executive Officer — 52,500 $0.00 $0
2025-12-12 BARBIERI ALLEN Officer and Director — 30,000 $0.00 $0
2025-12-12 MOATAZEDI DAVID Director — 20,000 $0.00 $0
2025-12-12 HUFF GARY M Director — 20,000 $0.00 $0
2025-12-12 CHIN ERIC Director — 22,500 $0.00 $0
2025-12-12 LU GARY Chief Financial Officer — 40,000 $0.00 $0
2024-12-13 IRANI ZACKARY S Chief Executive Officer — 250,000 $0.31 $77,500
2024-12-13 BARBIERI ALLEN Officer and Director — 110,000 $0.31 $34,100
2024-12-13 EMERSON JANE Director — 85,000 $0.31 $26,350
2024-12-13 MOATAZEDI DAVID Director — 85,000 $0.31 $26,350
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Total Revenue
5.31
-1.92%
5.42
+1.42%
5.34
-71.71%
18.87
Operating Revenue
5.31
-1.92%
5.42
+1.42%
5.34
-71.71%
18.87
Cost Of Revenue
4.81
+0.19%
4.80
-1.82%
4.89
-69.21%
15.89
Reconciled Cost Of Revenue
4.81
+0.19%
4.80
-1.82%
4.89
-69.21%
15.89
Gross Profit
0.50
-18.49%
0.61
+37.00%
0.45
-85.02%
2.98
Operating Expense
5.63
-19.25%
6.98
-9.01%
7.67
+2.10%
7.51
Research And Development
1.02
-31.39%
1.49
-5.87%
1.58
-12.58%
1.81
Selling General And Administration
4.61
-15.95%
5.49
-9.83%
6.08
+6.77%
5.70
Total Expenses
10.45
-11.32%
11.78
-6.21%
12.56
-46.33%
23.41
Operating Income
-5.14
+19.32%
-6.37
+11.85%
-7.22
-59.31%
-4.53
Total Operating Income As Reported
-5.14
+19.32%
-6.37
+11.85%
-7.22
-59.31%
-4.53
EBITDA
-4.74
+20.96%
-5.99
+12.79%
-6.87
-74.46%
-3.94
Normalized EBITDA
-4.74
+20.96%
-5.99
+12.79%
-6.87
-74.46%
-3.94
Reconciled Depreciation
0.40
+6.95%
0.37
+6.55%
0.35
-41.01%
0.59
EBIT
-5.14
+19.32%
-6.37
+11.85%
-7.22
-59.31%
-4.53
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Net Income
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Pretax Income
-4.97
+16.24%
-5.94
+16.26%
-7.09
-57.29%
-4.51
Net Non Operating Interest Income Expense
0.17
-61.72%
0.43
+224.06%
0.13
+392.59%
0.03
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
0.17
-61.72%
0.43
+224.06%
0.13
+392.59%
0.03
Interest Expense
—
—
—
0.00
Interest Income Non Operating
0.17
-61.72%
0.43
+224.06%
0.13
+392.59%
0.03
Interest Income
0.17
-61.72%
0.43
+224.06%
0.13
+392.59%
0.03
Other Income Expense
—
—
0.00
—
Other Non Operating Income Expenses
—
—
0.00
—
Gain On Sale Of Security
—
—
—
—
Tax Provision
0.00
-97.62%
0.04
-17.65%
0.05
+112.50%
0.02
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Net Income From Continuing Operation Net Minority Interest
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Net Income From Continuing And Discontinued Operation
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Net Income Continuous Operations
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Normalized Income
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Net Income Common Stockholders
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Diluted EPS
-2.16
+23.94%
-2.84
+29.00%
-4.00
-38.89%
-2.88
Basic EPS
-2.16
+23.94%
-2.84
+29.00%
-4.00
-38.89%
-2.88
Basic Average Shares
2.30
+9.22%
2.10
+18.87%
1.77
+11.69%
1.58
Diluted Average Shares
2.30
+9.22%
2.10
+18.87%
1.77
+11.69%
1.58
Diluted NI Availto Com Stockholders
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Total Assets
5.95
-35.76%
9.25
-35.98%
14.45
+27.08%
11.37
Current Assets
4.88
-36.94%
7.73
-39.59%
12.80
+35.75%
9.43
Cash Cash Equivalents And Short Term Investments
2.40
-42.47%
4.17
-57.09%
9.72
+64.26%
5.92
Cash And Cash Equivalents
2.40
-42.47%
4.17
-57.09%
9.72
+64.26%
5.92
Receivables
0.73
-22.81%
0.95
+31.16%
0.72
-6.72%
0.77
Accounts Receivable
0.73
-22.81%
0.95
+31.16%
0.72
-6.72%
0.77
Gross Accounts Receivable
0.76
-21.64%
0.97
+28.63%
0.75
-18.99%
0.93
Allowance For Doubtful Accounts Receivable
-0.03
-36.84%
-0.02
+34.48%
-0.03
+81.05%
-0.15
Inventory
1.49
-37.29%
2.38
+15.56%
2.06
-14.90%
2.42
Raw Materials
1.07
-29.49%
1.52
-9.42%
1.68
-2.33%
1.72
Work In Process
0.74
-35.11%
1.15
+31.76%
0.87
+13.89%
0.76
Finished Goods
0.15
-17.88%
0.18
-1.65%
0.18
-76.73%
0.78
Prepaid Assets
—
0.24
-20.67%
0.30
-6.33%
0.32
Other Current Assets
0.26
+7.14%
0.24
-20.67%
0.30
-6.25%
0.32
Total Non Current Assets
1.07
-29.74%
1.52
-8.09%
1.66
-14.89%
1.95
Net PPE
0.56
-40.19%
0.94
-24.44%
1.25
-17.68%
1.52
Gross PPE
3.25
+0.00%
3.25
+1.60%
3.20
-9.87%
3.55
Accumulated Depreciation
-2.68
-16.45%
-2.30
-18.28%
-1.95
+4.04%
-2.03
Machinery Furniture Equipment
0.21
+0.00%
0.21
+0.00%
0.21
-7.05%
0.23
Other Properties
3.04
+0.00%
3.04
+1.71%
2.98
-10.06%
3.32
Goodwill And Other Intangible Assets
0.23
+7.55%
0.21
+28.48%
0.17
-2.94%
0.17
Other Intangible Assets
0.23
+7.55%
0.21
+28.48%
0.17
-2.94%
0.17
Investments And Advances
0.17
+0.00%
0.17
+0.00%
0.17
+0.00%
0.17
Other Non Current Assets
0.11
-44.33%
0.20
+156.96%
0.08
-17.71%
0.10
Total Liabilities Net Minority Interest
1.84
-30.90%
2.66
-2.45%
2.73
-10.46%
3.05
Current Liabilities
1.74
-21.05%
2.20
+13.32%
1.95
-3.28%
2.01
Payables And Accrued Expenses
0.67
-40.95%
1.14
+27.58%
0.89
-8.23%
0.97
Payables
0.29
-47.32%
0.56
+62.79%
0.34
-53.26%
0.74
Accounts Payable
0.29
-47.32%
0.56
+62.79%
0.34
-53.26%
0.74
Current Accrued Expenses
0.38
-34.78%
0.58
+5.47%
0.55
+132.20%
0.24
Pensionand Other Post Retirement Benefit Plans Current
0.66
+0.00%
0.66
-5.89%
0.70
+7.57%
0.65
Current Debt And Capital Lease Obligation
0.36
+9.82%
0.33
+9.76%
0.30
-12.90%
0.34
Current Capital Lease Obligation
0.36
+9.82%
0.33
+9.76%
0.30
-12.90%
0.34
Current Deferred Liabilities
0.06
-35.29%
0.09
+41.67%
0.06
+17.65%
0.05
Current Deferred Revenue
0.06
-35.29%
0.09
+41.67%
0.06
+17.65%
0.05
Other Current Liabilities
—
—
—
0.00
Total Non Current Liabilities Net Minority Interest
0.10
-78.21%
0.46
-41.53%
0.79
-24.37%
1.04
Long Term Debt And Capital Lease Obligation
0.10
-78.21%
0.46
-41.53%
0.79
-24.37%
1.04
Long Term Capital Lease Obligation
0.10
-78.21%
0.46
-41.53%
0.79
-24.37%
1.04
Stockholders Equity
4.11
-37.72%
6.59
-43.78%
11.72
+40.83%
8.32
Common Stock Equity
4.11
-37.72%
6.59
-43.78%
11.72
+40.83%
8.32
Capital Stock
0.20
+20.83%
0.17
-87.52%
1.35
+30.81%
1.03
Common Stock
0.20
+20.83%
0.17
-87.52%
1.35
+30.81%
1.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
2.55
+21.09%
2.10
+0.00%
2.10
+30.73%
1.61
Ordinary Shares Number
2.55
+21.09%
2.10
+0.00%
2.10
+30.73%
1.61
Additional Paid In Capital
57.17
+4.49%
54.72
+3.82%
52.70
+24.17%
42.45
Retained Earnings
-53.17
-10.32%
-48.20
-14.16%
-42.22
-20.36%
-35.08
Gains Losses Not Affecting Retained Earnings
-0.10
-2.94%
-0.10
+7.27%
-0.11
-48.65%
-0.07
Other Equity Adjustments
-0.10
-2.94%
-0.10
+7.27%
-0.11
-48.65%
-0.07
Total Equity Gross Minority Interest
4.11
-37.72%
6.59
-43.78%
11.72
+40.83%
8.32
Total Capitalization
4.11
-37.72%
6.59
-43.78%
11.72
+40.83%
8.32
Working Capital
3.13
-43.28%
5.53
-49.07%
10.85
+46.33%
7.42
Invested Capital
4.11
-37.72%
6.59
-43.78%
11.72
+40.83%
8.32
Total Debt
0.46
-41.66%
0.79
-27.45%
1.08
-21.54%
1.38
Capital Lease Obligations
0.46
-41.66%
0.79
-27.45%
1.08
-21.54%
1.38
Net Tangible Assets
3.88
-39.22%
6.38
-44.81%
11.56
+41.74%
8.15
Tangible Book Value
3.88
-39.22%
6.38
-44.81%
11.56
+41.74%
8.15
Inventories Adjustments Allowances
-0.47
-0.86%
-0.47
+30.51%
-0.67
+20.57%
-0.85
Investmentin Financial Assets
0.17
+0.00%
0.17
+0.00%
0.17
+0.00%
0.17
Line Item Trend 2025-05-31 2024-05-31 2023-05-31 2022-05-31
Operating Cash Flow
-3.84
+28.35%
-5.36
+2.06%
-5.47
-1042.80%
-0.48
Cash Flow From Continuing Operating Activities
-3.84
+28.35%
-5.36
+2.06%
-5.47
-1042.80%
-0.48
Net Income From Continuing Operations
-4.97
+16.81%
-5.98
+16.27%
-7.14
-57.58%
-4.53
Depreciation Amortization Depletion
0.40
+6.95%
0.37
+6.55%
0.35
-41.01%
0.59
Depreciation
0.40
+6.95%
0.37
+6.55%
0.35
-41.01%
0.59
Depreciation And Amortization
0.40
+6.95%
0.37
+6.55%
0.35
-41.01%
0.59
Stock Based Compensation
0.46
-45.04%
0.84
-29.37%
1.19
-5.95%
1.26
Provisionand Write Offof Assets
0.00
+101.95%
-0.20
-17.82%
-0.17
+88.05%
-1.46
Operating Gains Losses
—
—
—
0.05
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.05
Change In Working Capital
0.27
+168.89%
-0.39
-227.96%
0.30
-91.56%
3.60
Change In Receivables
0.21
+197.21%
-0.21
+26.12%
-0.29
-121.32%
1.36
Changes In Account Receivables
0.21
+197.21%
-0.21
+26.12%
-0.29
-121.32%
1.36
Change In Inventory
0.88
+866.96%
-0.12
-121.54%
0.53
-65.81%
1.56
Change In Prepaid Assets
-0.02
-127.42%
0.06
+210.00%
0.02
-60.00%
0.05
Change In Payables And Accrued Expense
-0.47
-326.83%
0.20
+761.29%
-0.03
-104.79%
0.65
Change In Accrued Expense
0.00
+102.44%
-0.04
-183.67%
0.05
-81.01%
0.26
Change In Payable
-0.47
-289.43%
0.25
+407.50%
-0.08
-120.57%
0.39
Change In Account Payable
-0.47
-289.43%
0.25
+407.50%
-0.08
-120.57%
0.39
Change In Other Working Capital
-0.02
-246.67%
0.01
-95.73%
0.35
+588.24%
0.05
Change In Other Current Assets
0.01
+118.18%
-0.04
-344.44%
0.02
-89.35%
0.17
Change In Other Current Liabilities
-0.33
-10.10%
-0.30
+0.00%
-0.30
-21.72%
-0.24
Investing Cash Flow
-0.04
+67.83%
-0.12
-47.44%
-0.08
+54.12%
-0.17
Cash Flow From Continuing Investing Activities
-0.04
+67.83%
-0.12
-47.44%
-0.08
+54.12%
-0.17
Net PPE Purchase And Sale
0.00
+100.00%
-0.05
+20.31%
-0.06
-12.28%
-0.06
Purchase Of PPE
0.00
+100.00%
-0.05
+20.31%
-0.06
-12.28%
-0.06
Capital Expenditure
-0.04
+67.83%
-0.12
-47.44%
-0.08
+54.12%
-0.17
Capital Expenditure Reported
-0.04
+42.19%
-0.06
-357.14%
-0.01
—
Net Intangibles Purchase And Sale
—
—
-0.01
+87.61%
-0.11
Purchase Of Intangibles
—
—
-0.01
+87.61%
-0.11
Financing Cash Flow
2.11
+2706.17%
-0.08
-100.86%
9.39
+292.23%
2.39
Cash Flow From Continuing Financing Activities
2.11
+2706.17%
-0.08
-100.86%
9.39
+292.23%
2.39
Net Common Stock Issuance
2.14
0.00
-100.00%
10.01
+316.90%
2.40
Common Stock Payments
—
0.00
+100.00%
-0.70
-729.41%
-0.09
Repurchase Of Capital Stock
—
0.00
+100.00%
-0.70
-729.41%
-0.09
Proceeds From Stock Option Exercised
0.01
0.00
-100.00%
0.08
+5.19%
0.08
Net Other Financing Charges
-0.05
+41.98%
-0.08
+88.51%
-0.70
-729.41%
-0.09
Changes In Cash
-1.77
+68.20%
-5.56
-244.79%
3.84
+120.07%
1.74
Effect Of Exchange Rate Changes
-0.00
-137.50%
0.01
+122.22%
-0.04
-38.46%
-0.03
Beginning Cash Position
4.17
-57.09%
9.72
+64.26%
5.92
+40.91%
4.20
End Cash Position
2.40
-42.45%
4.17
-57.09%
9.72
+64.26%
5.92
Free Cash Flow
-3.88
+29.18%
-5.48
+1.37%
-5.55
-755.47%
-0.65
Interest Paid Supplemental Data
—
—
—
—
Income Tax Paid Supplemental Data
0.01
-75.61%
0.04
-19.61%
0.05
+112.50%
0.02
Common Stock Issuance
2.14
0.00
-100.00%
10.01
+316.90%
2.40
Issuance Of Capital Stock
2.14
0.00
-100.00%
10.01
+316.90%
2.40
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category